Item 7.01 Regulation FD Disclosure.

On November 22, 2021, Deciphera Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the European Commission ("EC") approved QINLOCK® (ripretinib) in the European Union ("EU") for the treatment of adult patients with advanced gastrointestinal stromal tumor ("GIST") who have received prior treatment with three or more kinase inhibitors, including imatinib. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On November 22, 2021, the Company announced that the EC approved QINLOCK in the EU for the treatment of adult patients with GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit No.                                  Description

99.1                Press Release issued by Deciphera Pharmaceuticals, Inc. on
                  November 22, 2021, furnished herewith

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses